STRO earnings date and last-quarter result: last quarter miss, P/E -0.08. Updated 2026-07-23.
Sutro Biopharma (STRO) Research Hub
Sutro Biopharma (STRO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 8.89 USD (-4.72%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.08, market cap 0.23B. This hub links to the full technical, earnings and options research available for STRO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.89 USD (-4.72%) |
| 52-week range | 8.11 USD – 33.63 USD |
| Trend regime | Range |
| 14-day RSI | 23.2 (Oversold) |
| Trailing P/E | -0.08 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
Available research for STRO
Covered Call on STRO: how it works, illustrative setup around the real 8.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on STRO: how it works, illustrative setup around the real 8.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on STRO: how it works, illustrative setup around the real 8.89 USD price, max profit/loss, breakeven and when to use it. Educational.
STRO technical analysis: range, last 8.89 USD, RSI 23.2, 52w range 8.11 USD–33.63 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is STRO in?
Sutro Biopharma (STRO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is STRO in an uptrend or downtrend?
As of 2026-10-26, STRO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is STRO's trailing P/E ratio?
STRO's trailing P/E is -0.08, with a market cap of 0.23B. See the earnings research page for full valuation detail.